EGFR EXON 19 DELETION

EGFR外显子19的缺失在肺癌中最常见。在非小细胞肺癌中，这些缺失对egfr酪氨酸激酶抑制剂gefitinib、afatinib和erlotinib敏感。也有数据表明这一事件是肺腺癌的一个好的预后标志。
Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma.